{"id":"e7389-eribulin-mesylate","safety":{"commonSideEffects":[{"rate":"54","effect":"Neutropenia"},{"rate":"52","effect":"Anemia"},{"rate":"35","effect":"Peripheral neuropathy"},{"rate":"61","effect":"Nausea"},{"rate":"54","effect":"Fatigue"},{"rate":"48","effect":"Alopecia"},{"rate":"25","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eribulin mesylate is a non-taxane microtubule inhibitor derived from halichondrin B. It binds to microtubules and inhibits their growth phase while allowing shortening, leading to mitotic blockade and cancer cell death. It also exhibits anti-angiogenic properties and can reverse multidrug resistance.","oneSentence":"Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth and induces apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:31.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Liposarcoma"},{"name":"Other solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT04345913","phase":"PHASE1, PHASE2","title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-01","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT03237780","phase":"PHASE2","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":72},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT07480694","phase":"","title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03","conditions":"Treatment Efficacy","enrollment":400},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":"Metastatic Breast Cancer in the Liver","enrollment":90},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT05810870","phase":"PHASE2","title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-05-24","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":14},{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT07441512","phase":"PHASE2","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","status":"NOT_YET_RECRUITING","sponsor":"Hu Hai","startDate":"2026-03-15","conditions":"TNBC - Triple-Negative Breast Cancer, TNBC","enrollment":26},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":"Metastatic Breast Cancer","enrollment":201},{"nctId":"NCT06449222","phase":"PHASE2","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-26","conditions":"Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers","enrollment":83},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-03-27","conditions":"Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation","enrollment":302},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":1155},{"nctId":"NCT07406542","phase":"PHASE3","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-04-01","conditions":"Recurrent or Metastatic Breast Cancer","enrollment":400},{"nctId":"NCT06435429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-08-13","conditions":"Metastatic HER2-positive Breast Cancer","enrollment":550},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":"Metastatic Breast Cancer","enrollment":331},{"nctId":"NCT05104866","phase":"PHASE3","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer","enrollment":732},{"nctId":"NCT07007559","phase":"PHASE1, PHASE2","title":"ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies","status":"RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2025-04-28","conditions":"Breast Cancer, Metastatic","enrollment":80},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06279364","phase":"PHASE3","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-02-28","conditions":"Triple Negative Breast Cancer","enrollment":524},{"nctId":"NCT05374512","phase":"PHASE3","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Breast Cancer","enrollment":644},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":"Triple Negative Breast Cancer","enrollment":350},{"nctId":"NCT06957886","phase":"PHASE3","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-05-15","conditions":"HER2-low Breast Cancer","enrollment":566},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT05458674","phase":"PHASE2","title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","status":"RECRUITING","sponsor":"Criterium, Inc.","startDate":"2024-01-30","conditions":"Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer","enrollment":30},{"nctId":"NCT07333937","phase":"PHASE2","title":"Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-12-20","conditions":"Brest Cancer","enrollment":35},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT03331250","phase":"PHASE2","title":"Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-01-18","conditions":"Angiosarcoma, Epithelioid Hemangioendothelioma","enrollment":13},{"nctId":"NCT03202316","phase":"PHASE2","title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-11","conditions":"Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma","enrollment":37},{"nctId":"NCT07088263","phase":"PHASE3","title":"Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Breast Neoplasms","enrollment":192},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":"Triple Negative Breast Cancer","enrollment":254},{"nctId":"NCT06081959","phase":"PHASE3","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT03526679","phase":"PHASE1, PHASE2","title":"Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-07-12","conditions":"Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult","enrollment":30},{"nctId":"NCT07255612","phase":"PHASE2","title":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-11-04","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT02623972","phase":"PHASE2","title":"A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-02-26","conditions":"Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":22},{"nctId":"NCT06889610","phase":"PHASE2","title":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-04","conditions":"Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic","enrollment":95},{"nctId":"NCT05530057","phase":"PHASE2","title":"Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-02-18","conditions":"Advanced Breast Cancer","enrollment":180},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT04986579","phase":"PHASE2","title":"Scalp Cooling in MBC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-10-07","conditions":"Metastatic Breast Cancer, Chemotherapy-induced Alopecia","enrollment":120},{"nctId":"NCT06382142","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-21","conditions":"Triple-Negative Breast Cancer","enrollment":418},{"nctId":"NCT06006273","phase":"PHASE1","title":"A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-16","conditions":"Refractory Solid Tumors","enrollment":48},{"nctId":"NCT01676818","phase":"PHASE2","title":"Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2012-08-09","conditions":"Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer","enrollment":32},{"nctId":"NCT05570253","phase":"PHASE2","title":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-03","conditions":"Breast Cancer, Metastatic Triple-Negative Breast Cancer","enrollment":55},{"nctId":"NCT06957431","phase":"PHASE1","title":"Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-22","conditions":"Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma","enrollment":18},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":557},{"nctId":"NCT07205185","phase":"PHASE2","title":"A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":46},{"nctId":"NCT03264547","phase":"PHASE3","title":"A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2017-08-28","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT06732323","phase":"PHASE3","title":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-04","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":504},{"nctId":"NCT06942234","phase":"PHASE1, PHASE2","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-06-01","conditions":"Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer","enrollment":180},{"nctId":"NCT03361436","phase":"PHASE1","title":"Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2018-03-19","conditions":"Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm","enrollment":15},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":"HER2-positive Locally Advanced or Metastatic Breast Cancer","enrollment":226},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT03899805","phase":"PHASE2","title":"A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-06-04","conditions":"Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":57},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06263231","phase":"PHASE3","title":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intensity Therapeutics, Inc.","startDate":"2024-06-28","conditions":"Sarcoma,Soft Tissue","enrollment":333},{"nctId":"NCT05217693","phase":"PHASE1","title":"A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","startDate":"2022-06-01","conditions":"Solid Tumor","enrollment":288},{"nctId":"NCT06355024","phase":"PHASE2","title":"Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2024-05-11","conditions":"Triple-negative Breast Cancer","enrollment":10},{"nctId":"NCT00365157","phase":"PHASE1, PHASE2","title":"Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-10-23","conditions":"Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":132},{"nctId":"NCT06590558","phase":"PHASE1","title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-04","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma","enrollment":""},{"nctId":"NCT06343948","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-04-24","conditions":"HR+HER2- Breast Cancer","enrollment":383},{"nctId":"NCT06383767","phase":"PHASE3","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-07-11","conditions":"Metastatic Breast Cancer","enrollment":378},{"nctId":"NCT05041101","phase":"PHASE1, PHASE2","title":"Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-21","conditions":"Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma","enrollment":6},{"nctId":"NCT06533722","phase":"PHASE2","title":"Adaptive Therapy for Post-Second-Line Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2024-08-04","conditions":"HER2-negative Metastatic Breast Cancer","enrollment":10},{"nctId":"NCT02061085","phase":"PHASE2","title":"Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment","status":"COMPLETED","sponsor":"MedSIR","startDate":"2013-07","conditions":"Breast Neoplasm, Metastasis","enrollment":53},{"nctId":"NCT06678048","phase":"PHASE2","title":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-23","conditions":"Breast Cancer","enrollment":12},{"nctId":"NCT03222856","phase":"PHASE2","title":"Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-12-14","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":"Breast Cancer Stage IV","enrollment":246},{"nctId":"NCT04013217","phase":"PHASE1","title":"Evaluate Eribulin ORA in Subjects With Solid Tumors","status":"TERMINATED","sponsor":"Health Hope Pharma","startDate":"2019-07-29","conditions":"Solid Tumor","enrollment":10},{"nctId":"NCT06775236","phase":"PHASE1, PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":"Advanced Solid Tumors, Breast Cancer","enrollment":410},{"nctId":"NCT02492711","phase":"PHASE3","title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-08-24","conditions":"HER-2 Positive Breast Cancer, Metastatic Neoplasm","enrollment":624},{"nctId":"NCT06857305","phase":"PHASE3","title":"Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ma Fei，MD","startDate":"2023-07-13","conditions":"Breast Cancer Metastatic","enrollment":192},{"nctId":"NCT05619913","phase":"PHASE2","title":"EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma","status":"RECRUITING","sponsor":"Australia New Zealand Gynaecological Oncology Group","startDate":"2023-05-22","conditions":"Ovarian Carcinosarcoma, Uterine Carcinosarcoma","enrollment":30},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06734533","phase":"","title":"Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-12-05","conditions":"HR+ Breast Cancer","enrollment":80},{"nctId":"NCT06731153","phase":"PHASE2","title":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12","conditions":"Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT06678230","phase":"PHASE2","title":"Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2024-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT01827787","phase":"PHASE2","title":"Eribulin in HER2 Negative Metastatic BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-05","conditions":"Breast Cancer","enrollment":83},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":"Metastatic Breast Cancer","enrollment":543},{"nctId":"NCT03840772","phase":"PHASE2","title":"Eribulin in Advanced Solitary Fibrous Tumor","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2019-07-17","conditions":"Solitary Fibrous Tumor","enrollment":16},{"nctId":"NCT02681523","phase":"PHASE2","title":"ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2015-10-28","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT02037529","phase":"PHASE3","title":"Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer","status":"SUSPENDED","sponsor":"Academic and Community Cancer Research United","startDate":"2014-01-17","conditions":"Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma","enrollment":201},{"nctId":"NCT06539559","phase":"PHASE2","title":"Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wang Jiayu","startDate":"2024-08-01","conditions":"Breast Neoplasms, Neoplasm Metastasis, Drug Therapy","enrollment":60},{"nctId":"NCT06387628","phase":"PHASE2","title":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-10","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":74},{"nctId":"NCT04464174","phase":"PHASE2","title":"Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-08","conditions":"Triple Negative Breast Cancer","enrollment":54},{"nctId":"NCT06355037","phase":"PHASE2","title":"Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-05-20","conditions":"Triple-negative Breast Cancer","enrollment":10},{"nctId":"NCT03393741","phase":"","title":"Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-29","conditions":"Breast Cancer, Breast Neoplasms","enrollment":5},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT02035813","phase":"PHASE2","title":"DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2014-01","conditions":"HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"E7389 (Eribulin Mesylate)","genericName":"E7389 (Eribulin Mesylate)","companyName":"Eisai Co., Ltd.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eribulin Mesylate, also known as E7389, is a small molecule inhibitor that targets tubulin. It is used to treat various conditions related to breast cancer, including metastatic breast cancer, advanced breast cancer, and triple negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}